<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03578406</url>
  </required_header>
  <id_info>
    <org_study_id>XQDC20180520</org_study_id>
    <nct_id>NCT03578406</nct_id>
  </id_info>
  <brief_title>HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer</brief_title>
  <official_title>Two-Arm Open-Labeled Trial of HPV-E6-Specific TCR-T Cells With or Without Anti-PD1 Auto-secreted Element in the Treatment of HPV-Positive Head and Neck Carcinoma or Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TCRCure Biotech Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xinqiao Hospital of Chongqing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human papillomavirus infections 16 (HPV16) is known to be a high-risk factor to induce&#xD;
      cervical cancers. To date, HPV16-related cervical cancer is still a major concern in&#xD;
      developing countries where vaccination is not prevalent. Concurrent therapies for cervical&#xD;
      cancers have limited response rate and high chance of relapse. However, HPV16-induced cancers&#xD;
      provided an ideal target for T cell-based immunotherapy due to the non-self origins.&#xD;
      Engineered T cells bearing a TCR (TCR-T) that can specifically recognize the presented HPV&#xD;
      antigen become a viable approach to treat this type of cancer. Though engineered T therapies&#xD;
      have been well-recognized in hematological cancers, solid cancer treatment has been a major&#xD;
      hurdle due to the immune-suppressive tumor microenvironment. One key mechanism of&#xD;
      tumor-elicited suppression is the PDL1-PD1 interaction which induces T cell exhaustion.&#xD;
      Therefore, TCR-T cells armed with a PD1 antagonist could further enhance the efficacy of&#xD;
      TCR-T in solid cancers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Determine the Maximum Tolerated Dose</measure>
    <time_frame>8 weeks</time_frame>
    <description>Verify the MTD of TCR-T cells for HPV16 E6 antigen for treatment. Nine patients will be enrolled in this project, using a dose-climbing approach, with every three patients as a group. The first group of patients returned to 5x106/kg TCR-T cells, the second group returned to 1x107/kg TCR-T cells, and the third group returned to 5x107/kg TCR-T cells</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>HPV TCR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPV E6-specific TCR-T cell</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HPV TCR-T with anti-PD1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPV E6-specific TCR-T cell with anti-PD1 auto-secreted element</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPV E6-specific TCR-T cells</intervention_name>
    <description>Patients were infused with HPV E6-specific TCR-T cells</description>
    <arm_group_label>HPV TCR-T</arm_group_label>
    <arm_group_label>HPV TCR-T with anti-PD1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Expected to live longer than 12 weeks&#xD;
&#xD;
          -  PS 0-2&#xD;
&#xD;
          -  Pathology confirmed as HPV16 positive malignant tumor, either metastatic or recurrent&#xD;
             disease&#xD;
&#xD;
          -  Creatinine &lt;2.5mg/dl&#xD;
&#xD;
          -  ALT/AST is lower than three times ULN.&#xD;
&#xD;
          -  No contraindications of leukocyte collection&#xD;
&#xD;
          -  Before entering the trial, women must adopt a reliable method of contraception until&#xD;
             30 days after infusion.&#xD;
&#xD;
          -  Understand this trial and have signed an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with symptomatic brain metastasis&#xD;
&#xD;
          -  With other uncontrolled malignant tumors.&#xD;
&#xD;
          -  Hepatitis B or Hepatitis C activity period, HIV infected patients&#xD;
&#xD;
          -  Any other uncontrolled disease that interferes with the trial&#xD;
&#xD;
          -  Patients with severe heart and cerebrovascular diseases such as coronary heart&#xD;
             disease, angina pectoris, myocardial infarction, arrhythmia, cerebral thrombosis and&#xD;
             cerebral hemorrhage&#xD;
&#xD;
          -  Untreated hypertension or hypertensive patients&#xD;
&#xD;
          -  A person with a history of mental illness that is difficult to control&#xD;
&#xD;
          -  Researchers do not consider it appropriate to participate in this trial&#xD;
&#xD;
          -  Patients who have been using immunosuppressive agents for a long time after organ&#xD;
             transplants, except for recent or current inhaled corticosteroids&#xD;
&#xD;
          -  Subjects who have been pregnant or nursing, or who plan for pregnancy within 2 months&#xD;
             of treatment or after the end of treatment&#xD;
&#xD;
          -  An illness affects a person who signs a written consent or complies with a study&#xD;
             procedure, or who is unwilling or unable to comply with the research requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Zhu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncology of Department, Xinqiao Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qingzhu Jia</last_name>
    <phone>+8615223334184</phone>
    <phone_ext>+8615223334184</phone_ext>
    <email>jiaqingzhu0801@outlook.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qingzhu Jia</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingzhu Jia</last_name>
      <phone>+8615223334184</phone>
      <phone_ext>+8615223334184</phone_ext>
      <email>jiaqingzhu0801@outlook.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 28, 2018</study_first_submitted>
  <study_first_submitted_qc>June 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2018</study_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinqiao Hospital of Chongqing</investigator_affiliation>
    <investigator_full_name>Qingzhu Jia, M.D.</investigator_full_name>
    <investigator_title>Secretary of Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

